Strides Pharma Science Limited has informed the Exchange about press release dated 14-Nov-2022 titled Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis.